Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib + temozolomide for advanced soft tissue sarcoma (Phase I/II)
ChiCTR2200062822Phase 2Not yet recruiting
- Sponsor
- Department of Orthopaedic Oncology, First Affiliated Hospital of Sun Yat-sen University
- Start
- Jul 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluzoparib and temozolomide in soft tissue sarcoma (STS), sponsored by Department of Orthopaedic Oncology, First Affiliated Hospital of Sun Yat-sen University. Primary endpoints: Safety (Phase I) and Objective Response Rate (Phase II, ORR). Planned start Jul 2022; status: not yet recruiting.
02
Drugs
fluzoparibtemozolomide
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on ChiCTR2200062822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062822.